ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2024

Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries.

Hyunjung Woo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.